福元医药：氨氯地平贝那普利胶囊获药品注册证书

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating approval for production and use in hypertension treatment [1] Group 1: Drug Approval Details - The approved drug contains Amlodipine (5mg) and Benazepril (10mg) per capsule and is intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone [1] - The drug was originally developed by Novartis and was first approved in the United States in March 1995 [1] - The company received the application acceptance notice on March 21, 2024, and has now obtained the drug registration certificate, which is considered equivalent to passing the consistency evaluation according to national policies [1]